Logo image
PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo
期刊文章   開放取用(OA)

PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo

Kun-Chun Chiang, Huang-Yang Chen, Shu-Yuan Hsu, Jong-Hwei S. Pang, Shang-Yu Wang, Jun-Te Hsu, Li-Wei Chen, Sheng-Fong Kuo, Chi-Chin Sun, Jim-Ming Lee, …
Drug Design, Development and Therapy, 卷.9, 頁碼.4631-4638
08/2015
PMID: 26316702

摘要

Breast cancer Cell cycle MCF-7 PTEN Target therapy Tumor growth Pharmacology Pharmaceutical Science Drug Discovery
Phosphatase and tensin homolog (PTEN), a well-known tumor suppressor gene and frequently mutated or lost in breast cancer, possesses the negative regulation function over the PI3K/Akt/mTOR pathway. PTEN insufficiency has been associated with advanced breast cancer and poor prognosis of breast cancer patients. Recently, target therapies aimed at PI3K/Akt/mTOR pathway to treat breast cancer have got popularity. However, the exact effect of PTEN on breast cancer cells is still not well understood. This study demonstrated that PTEN knockdown in MCF-7 cells strengthened the downstream gene expressions, including p-Akt, p-ERK1/2, p-mTOR, p-p70s6k, and p-GSK3β. PTEN knockdown MCF-7 cells had increased cell growth and Ki-67 expression. Further Western blot demonstrated that p27 was repressed obviously with p21 slightly inhibited and CDK1, 2, 4, 6, cyclin A, and Cdc25C were upregulated in MCF-7 PTEN knockdown cells, leading to the higher growth rate. More importantly, PTEN knockdown MCF-7 cells had higher tumorigenesis and tumor growth in vivo. From our current work, we provided more detailed PTEN-mediated mechanisms to stimulate ER+ breast cancer cell growth. Our result may pave the way for further target therapy development used alone or in combination with other drugs for ER+ breast cancer with PTEN insufficiency.

檔案與連結 (1)

url
https://doi.org/10.2147/DDDT.S86184檢視
已出版(紀錄版本) 開放

相關連結

指標

1 檢視次數

詳細資料

Logo image